1. Home
  2. UVSP vs GYRE Comparison

UVSP vs GYRE Comparison

Compare UVSP & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UVSP
  • GYRE
  • Stock Information
  • Founded
  • UVSP 1876
  • GYRE 2002
  • Country
  • UVSP United States
  • GYRE United States
  • Employees
  • UVSP N/A
  • GYRE N/A
  • Industry
  • UVSP Major Banks
  • GYRE Biotechnology: Pharmaceutical Preparations
  • Sector
  • UVSP Finance
  • GYRE Health Care
  • Exchange
  • UVSP Nasdaq
  • GYRE Nasdaq
  • Market Cap
  • UVSP 881.8M
  • GYRE 897.1M
  • IPO Year
  • UVSP 1989
  • GYRE N/A
  • Fundamental
  • Price
  • UVSP $30.66
  • GYRE $9.48
  • Analyst Decision
  • UVSP Hold
  • GYRE
  • Analyst Count
  • UVSP 3
  • GYRE 0
  • Target Price
  • UVSP $29.00
  • GYRE N/A
  • AVG Volume (30 Days)
  • UVSP 127.7K
  • GYRE 104.9K
  • Earning Date
  • UVSP 04-23-2025
  • GYRE 05-19-2025
  • Dividend Yield
  • UVSP 2.90%
  • GYRE N/A
  • EPS Growth
  • UVSP 11.32
  • GYRE N/A
  • EPS
  • UVSP 2.66
  • GYRE 0.05
  • Revenue
  • UVSP $294,306,000.00
  • GYRE $105,757,000.00
  • Revenue This Year
  • UVSP $8.70
  • GYRE $22.01
  • Revenue Next Year
  • UVSP $6.05
  • GYRE $88.14
  • P/E Ratio
  • UVSP $11.31
  • GYRE $184.08
  • Revenue Growth
  • UVSP 2.88
  • GYRE N/A
  • 52 Week Low
  • UVSP $20.37
  • GYRE $6.11
  • 52 Week High
  • UVSP $32.75
  • GYRE $19.00
  • Technical
  • Relative Strength Index (RSI)
  • UVSP 64.91
  • GYRE 55.23
  • Support Level
  • UVSP $29.93
  • GYRE $8.41
  • Resistance Level
  • UVSP $30.73
  • GYRE $9.98
  • Average True Range (ATR)
  • UVSP 0.85
  • GYRE 0.60
  • MACD
  • UVSP 0.26
  • GYRE 0.09
  • Stochastic Oscillator
  • UVSP 95.26
  • GYRE 70.93

About UVSP Univest Financial Corporation

Univest Financial Corp is engaged in domestic banking services for individuals, businesses, municipalities and non-profit organizations. The bank has three operating segments; Banking segment provides financial services including a full range of banking services such as deposit taking, loan origination, and servicing, mortgage banking, other general banking services, and equipment lease financing, Wealth Management segment offers investment advisory, financial planning, trust and brokerage services, and The Insurance segment includes a full-service insurance brokerage agency offering commercial property and casualty insurance, employee benefits solutions, personal insurance lines and human resources consulting. It generates majority of its revenue from the banking segment.

About GYRE Gyre Therapeutics Inc.

Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

Share on Social Networks: